uracil and Apoplexy
uracil has been researched along with Apoplexy in 6 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| " The EXAMINE trial confirmed noninferiority of the dipeptidyl dipeptidase 4 inhibitor alogliptin to placebo on major adverse cardiac event rates in a post-acute coronary syndrome (ACS) T2DM population." | 9.22 | Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care tria ( Bakris, GL; Cannon, CP; Cushman, WC; Kupfer, S; Liu, Y; Mehta, CR; Menon, V; Shimada, YJ; White, WB; Wilson, C; Zannad, F, 2016) |
| "In patients with type 2 diabetes and recent acute coronary syndromes, alogliptin did not increase the risk of heart failure outcomes." | 9.20 | Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Fleck, PR; Kupfer, S; Lam, H; Mehta, CR; Menon, V; Perez, AT; White, WB; Wilson, C; Zannad, F, 2015) |
| " The EXAMINE trial confirmed noninferiority of the dipeptidyl dipeptidase 4 inhibitor alogliptin to placebo on major adverse cardiac event rates in a post-acute coronary syndrome (ACS) T2DM population." | 5.22 | Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care tria ( Bakris, GL; Cannon, CP; Cushman, WC; Kupfer, S; Liu, Y; Mehta, CR; Menon, V; Shimada, YJ; White, WB; Wilson, C; Zannad, F, 2016) |
| "In patients with type 2 diabetes and recent acute coronary syndromes, alogliptin did not increase the risk of heart failure outcomes." | 5.20 | Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Fleck, PR; Kupfer, S; Lam, H; Mehta, CR; Menon, V; Perez, AT; White, WB; Wilson, C; Zannad, F, 2015) |
| "Alogliptin did not increase the risk of either first or recurrent CV events when compared with placebo in patients with T2DM and recent acute coronary syndrome." | 2.87 | Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. ( Bergenstal, RM; Cannon, CP; Cavender, MA; Cushman, WC; Heller, S; Liu, Y; Massaro, JM; Mehta, CR; White, WB; Zannad, F, 2018) |
| "Early after an ACS, patients with type 2 diabetes mellitus experience a significant burden of HF events and recurrent ACS." | 2.87 | Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Liu, Y; Sharma, A; White, WB; Zannad, F, 2018) |
| "Alogliptin treatment recovered the reduction in occludin and ZO-1 induced by OGD/R." | 1.51 | The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells. ( Guo, AH; Han, XF; Hao, FL; Lu, XJ; Wang, XL; Zhao, XF; Zhao, ZR, 2019) |
Research
Studies (6)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Elharram, M | 1 |
| Sharma, A | 2 |
| White, W | 1 |
| Bakris, G | 1 |
| Rossignol, P | 1 |
| Mehta, C | 1 |
| Ferreira, JP | 1 |
| Zannad, F | 5 |
| Cavender, MA | 1 |
| White, WB | 4 |
| Liu, Y | 3 |
| Massaro, JM | 1 |
| Bergenstal, RM | 1 |
| Mehta, CR | 3 |
| Heller, S | 1 |
| Cushman, WC | 4 |
| Cannon, CP | 4 |
| Bakris, GL | 3 |
| Hao, FL | 1 |
| Han, XF | 1 |
| Wang, XL | 1 |
| Zhao, ZR | 1 |
| Guo, AH | 1 |
| Lu, XJ | 1 |
| Zhao, XF | 1 |
| Menon, V | 2 |
| Perez, AT | 1 |
| Fleck, PR | 1 |
| Kupfer, S | 2 |
| Wilson, C | 2 |
| Lam, H | 1 |
| Shimada, YJ | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome[NCT00968708] | Phase 3 | 5,380 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Percentage of Participants With Primary Major Adverse Cardiac Events (MACE)
Primary Major Adverse Cardiac Events were defined as a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 11.8 |
| Alogliptin | 11.3 |
Percentage of Participants With Secondary Major Adverse Cardiac Events (MACE)
Secondary MACE composite consisted of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or urgent revascularization due to unstable angina; these events were adjudicated by an independent cardiovascular endpoint committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-of date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 13.4 |
| Alogliptin | 12.7 |
Trials
5 trials available for uracil and Apoplexy
| Article | Year |
|---|---|
Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus.
Topics: Acute Coronary Syndrome; Comorbidity; Diabetes Mellitus, Type 2; Evidence-Based Practice; Female; He | 2020 |
Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female | 2018 |
Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double | 2018 |
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathie | 2015 |
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care tria
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; Hypoglyce | 2016 |
Other Studies
1 other study available for uracil and Apoplexy
| Article | Year |
|---|---|
The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells.
Topics: Animals; Brain; Brain Ischemia; Cells, Cultured; Endothelial Cells; Humans; Infarction, Middle Cereb | 2019 |